Northeast Investment Management Reduces Holdings in The Clorox Company (NYSE:CLX)

Northeast Investment Management cut its position in shares of The Clorox Company (NYSE:CLX - Free Report) by 4.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 51,547 shares of the company's stock after selling 2,677 shares during the quarter. Northeast Investment Management's holdings in Clorox were worth $7,590,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Redwood Park Advisors LLC purchased a new position in Clorox during the fourth quarter worth about $26,000. Millstone Evans Group LLC purchased a new position in Clorox in the fourth quarter valued at about $31,000. Wood Tarver Financial Group LLC purchased a new position in Clorox in the fourth quarter valued at about $31,000. Asset Planning Inc purchased a new position in Clorox in the fourth quarter valued at about $32,000. Finally, GKV Capital Management Co. Inc. purchased a new position in Clorox in the fourth quarter valued at about $32,000. 78.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Clorox

In related news, Director Pierre R. Breber bought 4,000 shares of the company's stock in a transaction dated Wednesday, May 7th. The stock was purchased at an average cost of $136.57 per share, with a total value of $546,280.00. Following the transaction, the director now owns 4,000 shares in the company, valued at approximately $546,280. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.57% of the stock is currently owned by corporate insiders.

Clorox Price Performance

Shares of NYSE:CLX traded up $0.99 during trading on Thursday, reaching $127.25. The company had a trading volume of 1,393,988 shares, compared to its average volume of 1,355,947. The company has a fifty day moving average of $135.18 and a two-hundred day moving average of $148.78. The stock has a market capitalization of $15.68 billion, a P/E ratio of 34.77, a price-to-earnings-growth ratio of 2.62 and a beta of 0.54. The Clorox Company has a 12 month low of $125.77 and a 12 month high of $171.37. The company has a current ratio of 0.94, a quick ratio of 0.60 and a debt-to-equity ratio of 20.52.

Clorox (NYSE:CLX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). Clorox had a return on equity of 316.87% and a net margin of 6.38%. The company had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.74 billion. During the same period in the previous year, the company earned $1.71 EPS. Clorox's quarterly revenue was down 8.0% on a year-over-year basis. Equities research analysts forecast that The Clorox Company will post 7.15 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on CLX. UBS Group dropped their target price on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Citigroup dropped their target price on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating on the stock in a research note on Monday, April 14th. Barclays lowered their price target on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating on the stock in a research report on Wednesday, May 7th. Wells Fargo & Company lowered their price target on shares of Clorox from $145.00 to $142.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 6th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $151.23.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.